Compare ABR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | RLAY |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | 653 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | ABR | RLAY |
|---|---|---|
| Price | $7.35 | $9.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $10.30 | ★ $16.86 |
| AVG Volume (30 Days) | ★ 3.7M | 2.4M |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 16.33% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $7.11 | $1.78 |
| 52 Week High | $12.58 | $11.49 |
| Indicator | ABR | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 44.95 |
| Support Level | $7.23 | $9.06 |
| Resistance Level | $7.95 | $9.54 |
| Average True Range (ATR) | 0.22 | 0.63 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 2.22 | 0.90 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).